What are the key safety monitoring considerations for aminoglycoside antibiotics?

• A. No monitoring is required beyond baseline labs.
• B. Nephrotoxicity and ototoxicity risk; monitor trough levels and renal function; adjust dosing for CrCl; avoid other nephrotoxic agents.
• C. Hepatotoxicity risk; monitor liver enzymes.
• D. Cardiac arrhythmia risk; monitor ECG.

Answer: (B)

Aminoglycosides have a narrow therapeutic index and pose real risks to the kidneys and inner ear, so safety monitoring is essential. The best approach focuses on preventing nephrotoxicity and ototoxicity by tracking drug exposure and organ function. Regularly check renal function (creatinine, GFR) and obtain trough drug levels to keep exposure within safe limits while ensuring enough antibiotic reaches the infection. Dosing should be adjusted based on creatinine clearance, and you should minimize additional nephrotoxic exposures—such as certain NSAIDs, contrast media, or other nephrotoxic drugs—during therapy. Clinically, watch for signs of kidney injury (rising creatinine, reduced urine output) and ototoxic effects (tinnitus, hearing loss, balance problems). This combination of trough level monitoring, renal function assessment, and careful dosing adjustment captures the central safety strategy for aminoglycosides.